Amgen Falls on Rival Trial Failure Despite Sound Fundamentals

• Our read: Amgen Inc carries a B grade among Healthcare peers in the S&P 500, resting on high earnings quality against narrower liquidity.
• The day: Shares fell 10.1% to $393.17 after a competitor's failed clinical trial cast doubt on a shared cardiovascular mechanism.
• Watching: Clinical development progress and outcome data for Amgen's late-stage cholesterol candidate olpasiran.

Amgen Inc shares fell 10.1% on Tuesday, September 8, marking the stock's largest single-day drop over the past year. The catalyst came from across the industry, where Novartis announced that its Phase 3 trial for pelacarsen failed to meet its primary cardiovascular endpoint. Although pelacarsen successfully lowered lipoprotein(a) levels, the treatment did not reduce the incidence of major events such as heart attacks and strokes compared to placebo.

The negative outcome hit AMGN because the company is developing olpasiran, a rival therapy designed to lower the same lipoprotein particle. The competitor's clinical failure prompted widespread concern among investors over whether reducing lipoprotein(a) produces tangible cardiovascular benefits. Pressure intensified as the shares absorbed an analyst downgrade to Market Perform citing patent expirations and a less favorable risk-reward balance. The selloff completely overshadowed Amgen's own positive Phase 3 trial results showing improved survival in small cell lung cancer for its drug Imdelltra.

The sudden pipeline revaluation lands on a company that entered the session with sturdy operating numbers. EasyAlpha grades Amgen Inc a B relative to Healthcare companies in the S&P 500. Across historical cycles, businesses graded A or B have demonstrated stronger financial foundations and a lower risk of severe drawdowns than those in the D or E tiers. Amgen's grade is anchored by standout earnings quality, reflected in a profit margin of 23.0% and a return on equity of 91.5%.

Trading volume surged to 3.1x the 20-session average as the market digested the pipeline news. While the decline interrupted a strong run, the shares remain +20.1% so far this year and trade at 18.2 times forward earnings. Wall Street expectations remain closely aligned with the current price, with the average analyst target of $389.69 sitting 0.9% from Tuesday's close.